High-throughput screening of dual-target inhibitors for SARS-CoV-2 main protease and papain-like protease from Chebulae Fructus: in silico prediction and experimental verification
2024

Dual-target inhibitors from Chebulae Fructus against SARS-CoV-2

publication 10 minutes Evidence: moderate

Author Information

Author(s): Wang Changjian, Cao Yipeng, Yang Qi, Wang Xinyue, Yang Zhiying, Yang Jingjing, Li Xinru, Li Bin, Wang Yuefei, Zhang Min

Primary Institution: State Key Laboratory of Chinese Medicine Modernization, Tianjin University of Traditional Chinese Medicine, Tianjin, China

Hypothesis

Can compounds from Chebulae Fructus effectively inhibit SARS-CoV-2 main protease and papain-like protease?

Conclusion

PGG and TGG are promising dual-target inhibitors of SARS-CoV-2 that may help avoid drug resistance.

Supporting Evidence

  • Eight compounds were identified as potential dual-target inhibitors through molecular docking.
  • PGG and TGG showed good inhibitory activities with IC50 values ranging from 1.33 to 27.37 μM.
  • Both compounds displayed antiviral activity in vitro against SARS-CoV-2 variants.
  • Molecular dynamics simulations indicated stability of the complexes over 500 ns.
  • PGG and TGG may help avoid drug resistance due to their dual-target approach.

Takeaway

Scientists found two natural compounds that can help fight the virus that causes COVID-19 by stopping it from making copies of itself.

Methodology

The study used molecular docking, FRET, SPR assays, and antiviral activity tests in Vero E6 cells to evaluate the compounds.

Limitations

The study primarily focused on in vitro results, which may not fully represent in vivo efficacy.

Digital Object Identifier (DOI)

10.3389/fmicb.2024.1510665

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication